VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results

Posted on: Tue, 17 Nov 2009 16:01:00 EST


Symbols: VVUS
MOUNTAIN VIEW, Calif., Nov 17, 2009 /PRNewswire-FirstCall via COMTEX/ --
VVUS | Quote | Chart | News | PowerRating -- VIVUS, Inc. (Nasdaq: VVUS | Quote | Chart | News | PowerRating) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-776-0853

International callers: 1-913-312-0980

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.


CONTACT:

VIVUS, Inc. Investor Relations: The Trout Group
Timothy E. Morris Brian Korb
Chief Financial Officer 646-378-2923
650-934-5200

Media Relations: Pure Communications, Inc.
Dan Budwick
973-271-6085

SOURCE VIVUS, Inc.

http://www.vivus.com

For full details on Vivus Inc (VVUS) VVUS. Vivus Inc (VVUS) has Short Term PowerRatings at TradingMarkets. Details on Vivus Inc (VVUS) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.